ALK and non-small cell lung carcinoma: With regard to ALK rearrangement, the PROFILE trials have shown that the first-generation TKI crizotinib obtained high rates of extracranial ORR in ALK-positive stage IV NSCLC patients (59.8–74%), but the effect on BMs was much more modest [72].